This article is more than 5 years old. Information may no longer be current.
Sitagliptin, omarigliptin lead to similar improvements in glycemic control
Click Here to Manage Email Alerts
The addition of the DPP-IV inhibitors once-daily sitagliptin or once-weekly omarigliptin results in similar safety and efficacy for patients with type 2 diabetes treated with metformin, study data show.
Ira Gantz, MD, a clinical researcher for metabolism at Merck Research Laboratories, and colleagues evaluated adults (mean age, 57.3 years) with type 2 diabetes (mean duration, 7 years; mean baseline HbA1c, 7.5%) randomly assigned to once-daily sitagliptin 100 mg (Januvia, Merck; n = 320) or once-weekly omarigliptin 25 mg (MK-3102, Merck; n = 322) to determine the safety and efficacy of each. Participants were recruited from 97 sites in 13 countries. The study treatments were administered for 24 weeks.
Mean change in baseline HbA1c was similar between the two treatment groups at 24 weeks (omarigliptin, –0.47% vs. sitagliptin, –0.43%). Reduction in fasting plasma glucose, rate of participants who achieved HbA1c less than 7% and less than 6.5% and rate of participants who received rescue therapy at or before 24 weeks (omarigliptin, 1.6% vs. sitagliptin, 1.9%) were also similar between the two treatment groups.
Overall, reported adverse events and serious adverse were similar between the two groups.
“In this Phase 3 study, the once-weekly DPP-IV inhibitor omarigliptin was found to be noninferior to the once-daily DPP-IV inhibitor sitagliptin at reducing patients’ HbA1c levels from baseline, with similar HbA1c reductions achieved in both groups,” Gantz told Endocrine Today. “This trial assessed the efficacy, safety and tolerability of omarigliptin 25 mg once-weekly compared to sitagliptin 100 mg once-daily in adults with type 2 diabetes who experienced inadequate glycemic control while taking metformin. The primary efficacy endpoint was noninferiority of omarigliptin to sitagliptin in decreasing HbA1c levels from baseline to week 24. The study achieved its primary efficacy endpoint on noninferior reductions in HbA1c for omarigliptin compared to sitagliptin at 24 weeks.” – by Amber Cox
Disclosure: One of the researchers reports receiving research payments from Merck and personal fees from Abbott, AstraZeneca, Amgen, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi, Servier, Takeda and Valeant. Gantz and the other researchers are employees of Merck.
Click Here to Manage Email Alerts